Astec Industries designs, engineers, manufactures and markets equipment and components used primarily in road building and related construction activities as well as other products. The company also manufactures certain equipment and components unrelated to road construction, including equipment for the mining, quarrying, construction and demolition industries and port and rail yard operators; gas and oil drilling rigs; water well and geothermal drilling rigs; industrial heat transfer equipment; commercial whole-tree pulpwood chippers; horizontal grinders; blower trucks; concrete plants; wood pellet plants; commercial and industrial burners; and combustion control systems.

BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company's commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

Robinson (C.H.) Worldwide is a third party logistics company. The company provides freight transportation services and logistics solutions to companies. The company's segments are: North American Surface Transportation, which provides freight transportation services across North America through a network of offices; and Global Forwarding, which provides global logistics services through an international network of offices and also contracts with independent agents; and All Other and Corporate, which includes Robinson Fresh? that provides sourcing services including the buying, selling, and marketing of fresh fruits, vegetables, and other perishable items, and managed services that provides Managed TMS?.

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in immunology, inflammation and oncology. The company has four clinical-stage product candidates: GB001 (Prostaglandin D2 receptor 2 Antagonist), which is for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions; GB002 (Platelet-derived growth factor Receptor Kinase Inhibitor), which is for the treatment of pulmonary arterial hypertension; GB004 (Hypoxia inducible factor-1a Stabilizer), which is for the treatment of inflammatory bowel disease; and GB1275 (CD11b Modulator), which is for the treatment of oncology indications.

ImmunoGen is a clinical-stage biotechnology company focused on developing antibody-drug conjugates (ADCs). An ADC with the company's proprietary technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. The company's main program is mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, a cell-surface protein overexpressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. The company is developing IMGN632 in clinical trials for patients with acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.

LGI Homes is a holding company. Through its subsidiaries, the company is engaged in the design, construction, and sale of new homes in markets in Texas, Arizona, Florida, Georgia, New Mexico, South Carolina, North Carolina, Colorado, Washington, Tennessee, Minnesota, Oklahoma, Alabama, California, Oregon, and Nevada. The company's product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under its LGI Homes brand, and its luxury series homes, which are sold under its Terrata Homes brand. The company's homebuilding operations are organized and managed by seven divisions: West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic.

McCormick & Co. manufactures, markets and distributes spices, seasoning mixes, condiments and other flavor products to the food industry- retailers, food manufacturers and foodservice businesses. The company also is partner in a number of joint ventures that are involved in the manufacture and sale of flavor products. The company's business segments comprised of: consumer, in which the company markets its products to customers and supplies private label items, known as store brands; and flavor solutions, which provides a range of flavor solutions including seasoning blends, spices and herbs, condiments, coating systems and compound flavors.

PulteGroup through its subsidiaries is engaged in the homebuilding business. The company also has mortgage banking operations, conducted principally through its susidiary, Pulte Mortgage LLC, and title and insurance brokerage operations. The company's homebuilding business includes the acquisition and development of land primarily for residential purposes within the United States. The company provides a variety of home designs, including single-family detached, townhouses, condominiums, and duplexes at different prices and with varying levels of options and amenities to its customer groups: first-time, move-up, and active adult.

RenaissanceRe Holdings is a holding company. Through its subsidiaries, the company is a global provider of reinsurance and insurance. The company's segments are: Property, which includes its catastrophe class of business, comprising excess of loss reinsurance and excess of loss retrocessional reinsurance to insure insurance and reinsurance companies against natural and man-made catastrophes, and its other property class of business, comprising proportional reinsurance, property per risk, property (re)insurance, binding facilities and regional United States multi-line reinsurance; and Casualty and Specialty, in which the company provides its casualty and specialty reinsurance products and excess of loss coverage.

Tricida is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal tract.

Universal Insurance Holdings is a holding company. Through its subsidiaries, the company provides property and casualty insurance and insurance services. The company's products and services include: Insurance Products, which provide various types of personal residential insurance such as homeowners, renters/tenants, condo unit owners, and dwelling/fire; Risk Management, in which its subsidiary, Evolution Risk Advisors, Inc., advises on actuarial issues, oversees distribution, administers claims payments, performs policy administration and underwriting, and assists with reinsurance negotiations; and Distribution, which provides policies through its direct-to-consumer online distribution platforms.

Vertex Pharmaceuticals is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and developing research and development programs in other indications. The company's marketed products are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. The company is evaluating CTX001, a genetic therapy as a potential treatment for sickle cell disease and beta-thalassemia.